Mentions
Extended reach
Total likes
Video views
AI synopsis
The posts mention that semaglutide did not increase bone formation and may raise markers of bone breakdown, with phrases like 'raises questions about its effects,' indicating a cautious tone. The discussion's tone varies from neutral references to cautious optimism about GLP-1s potentially protecting bone better than calorie restriction, reflecting balanced curiosity and skepticism based on study details.
The discussions reflect mixed opinions; some acknowledge the study's findings while others suggest potential benefits of GLP-1 receptor agonists for bone health, indicating neither strong agreement nor disagreement.
There is a moderate level of interest, with posts referencing specific markers like PINP and CTX and mentioning the need for more data, showing engagement with the study's details but not overwhelming enthusiasm.
Comments involve referencing the methodology and implications, such as the comparison of weight loss versus bone health, demonstrating thoughtful engagement without deep dives into technical specifics.
The conversation highlights concerns and questions about the clinical relevance, but overall, it seems preliminary, so the impact on practice or perception remains moderate.
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT In adults with increased fracture risk, semaglutide once weekly did not increase bone formation based on bone formation marker P-PINP https://t.co/NyCGsk1bqK @moSth8 @frost_nielsen https://t.co/PC05CyNLrm
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial (open access) https://t.co/Gb8ZlAiUKR
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial - eClinicalMedicine https://t.co/PHqZYkvZKJ
RT @eClinicalMed: Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT In adults with increased fr…
RT @eClinicalMed: Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT In adults with increased fr…
Intentional weight loss improves metabolic health but may harm bone. Semaglutide dropped weight by 9.4 percent but raised CTX, a marker of bone breakdown. GLP-1s might help protect bone better than calorie restriction, but more data is needed.
The study investigated the effects of once-weekly semaglutide on bone health in adults at increased fracture risk. Bone resorption increased, and bone density was lower in the treatment group, raising concerns about its…
The blockbuster drug Ozempic, once prescribed for diabetes, is increasingly used for weight loss. This video explores how the timing of meals can influence metabolism and body weight, addressing the gaps in long-term…
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial - eClinicalMedicine https://t.co/PHqZYkvZKJ
Intentional weight loss improves metabolic health but may harm bone. Semaglutide dropped weight by 9.4 percent but raised CTX, a marker of bone breakdown. GLP-1s might help protect bone better than calorie restriction, but more data is needed.
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial (open access) https://t.co/Gb8ZlAiUKR
RT @eClinicalMed: Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT In adults with increased fr…
RT @eClinicalMed: Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT In adults with increased fr…
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT In adults with increased fracture risk, semaglutide once weekly did not increase bone formation based on bone formation marker P-PINP https://t.co/NyCGsk1bqK @moSth8 @frost_nielsen https://t.co/PC05CyNLrm